The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Inclusion Criteria:

• 2 or more risk factors (according to NCEP ATP III guideline)
• Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

• Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
• Previous enrolment or randomisation of treatment in the present study.
• Participation in a clinical study during the last 90 days.

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.